Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Hits New 1-Year High – Time to Buy?

Shares of Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) hit a new 52-week high on Wednesday . The company traded as high as $52.25 and last traded at $52.25, with a volume of 0 shares changing hands. The stock had previously closed at $52.25.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Royal Bank of Canada upgraded Recordati Industria Chimica e Farmaceutica to a “hold” rating in a report on Monday, October 7th. Barclays upgraded shares of Recordati Industria Chimica e Farmaceutica to a “strong sell” rating in a report on Tuesday, October 22nd.

Recordati Industria Chimica e Farmaceutica Price Performance

The company has a quick ratio of 0.95, a current ratio of 1.36 and a debt-to-equity ratio of 0.73. The stock’s 50-day moving average is $52.21 and its 200-day moving average is $52.01. The firm has a market cap of $10.78 billion, a P/E ratio of 26.13 and a beta of 0.33.

About Recordati Industria Chimica e Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.